This article is more than 5 years old. Information may no longer be current.

Barely half of US adults plan to get flu vaccine, FDA OKs monkeypox, smallpox vaccine — top stories in infectious disease

Survey results that showed that only 52% of adults in the United States plan to get the vaccine for this flu season and the FDA’s approval of a vaccine for smallpox and monkeypox were among to top stories in infectious disease last week.

The FDA’s decision to fast track a novel treatment for Guillain-Barré syndrome was another top story.

Only 52% of US adults plan to get flu vaccine, survey shows

WASHINGTON — Although influenza vaccination rates have increased, new data released by the National Foundation for Infectious Diseases indicated that barely half of U.S. adults plan to get vaccinated against influenza this season. Read more.

FDA approves monkeypox, smallpox vaccine

Bavarian Nordic announced that the FDA has approved Jynneos, a live, nonreplicating vaccine for the prevention of smallpox and monkeypox disease in adults aged 18 years or older who are at a high risk for smallpox or monkeypox infection. Read more.

FDA fast tracks novel treatment for Guillain-Barré syndrome

The FDA has granted fast track designation to ANX005, a novel treatment for Guillain-Barré syndrome, Annexon Biosciences announced. Read more.

Not just Lyme: 22% of blacklegged ticks collected on Long Island carry multiple pathogens

Researchers collected three species of ticks from multiple locations in Suffolk County, Long Island, and identified a high prevalence of polymicrobial infections capable of causing human disease. Read more.

Bacille Calmette-Guérin vaccination associated with lower prevalence of latent tuberculosis infection in adults

Bacille Calmette-Guérin, or BCG, vaccination is associated with a lower prevalence of latent tuberculosis infection in adult TB contacts and could protect against Mycobacterium tuberculosis infection, according to results published in Journal of Infectious Diseases. Read more.